Latest database descriptions

To establish an observatory for the treatment of patients with hypertrophic cardiomyopathy (sarcomeric or non-sarcomeric). To specify the profile of HCM patients in France, methods for diagnosis and assessment (etiological and family survey), and therapeutic procedures.

To define the prevalence of TTR amyloidosis in a large population of patients attending the CMH.

Continuous epidemiological monitoring of health indicators.

Echocardiography-based study on the development of valvular disease (decrease, stable, increase) in patients treated with benfluorex.

To compare the development of valvular diseases potentially linked to benfluorex and diseases not linked to benfluorex.
- All patients and patients with valvular disease potentially linked to benfluorex; assessment of development with regards to:
- Indication(s), duration of exposure to benfluorex and duration since stopping medication.
- Age and sex;
- diabetes and associated medical treatment.
- Presence of cardiac and non-cardiac diseases;
- current treatments and treatments that were undergone simultaneously with benfluorex.